A carregar...
LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC
Gefitinib, a tyrosine kinase inhibitor of epidermal growth factor receptor, has been used as the first choice of treatment for advanced non-small-cell lung cancer. However, during the course of treatment, cancer cells often develop resistance to gefitinib without fully understood mechanisms. In this...
Na minha lista:
| Publicado no: | Mol Ther Nucleic Acids |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Gene & Cell Therapy
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6424064/ https://ncbi.nlm.nih.gov/pubmed/30889481 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omtn.2019.02.010 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|